Reimbursement Review Reports


( Last Updated : April 2, 2015)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Actemra Tocilizumab Arthritis, rheumatoid List with criteria/condition Complete
Actemra tocilizumab Giant cell arteritis (GCA) Reimburse with clinical criteria and/or conditions Complete
Actemra Tocilizumab Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete
Actemra Tocilizumab Arthritis, polyarticular juvenile idiopathic List with criteria/condition Complete
Actikerall Fluorouracil and Salicylic Acid Hyperkeratotic actinic keratosis Reimburse with clinical criteria and/or conditions Complete
Adcetris Brentuximab vedotin Hodgkin Lymphoma Reimburse with clinical criteria and/or conditions Complete
Adcetris Brentuximab Vedotin HL at high risk of relapse or progression post-ASCT Reimburse with clinical criteria and/or conditions Complete
Adcetris Brentuximab Vedotin Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) Reimburse with clinical criteria and/or conditions Complete
Adcetris Brentuximab vedotin Withdrawn
Adcetris Brentuximab Vedotin peripheral T-cell lymphoma (PTCL) Reimburse Complete